Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa. by Clouse, Kate et al.
Boston University
OpenBU http://open.bu.edu
Center for Global Health and Development Center for Global Health and Development Papers
2017-05
Mobility and Clinic Switching
Among Postpartum Women
Considered Lost to HIV Care in
South Africa.
Clouse K, Mongwenyana C, Musina M, Bokaba D, Long L, Maskew M, Ahonkhai A,
Fox MP. Acceptability and feasibility of a financial incentive intervention to improve
retention in HIV care among pregnant women in Johannesburg, South Africa. AIDS
care. 2017 Oct 25. 1-8. https://doi.org/10.1097/QAI.0000000000001284
https://hdl.handle.net/2144/31123
Boston University
Mobility and clinic switching among postpartum women 
considered lost to HIV care in South Africa
Kate Clouse, PhD, MPHa,b,c,*, Sten H. Vermund, MD, PhDa,d, Mhairi Maskew, MBBCh, MSc 
(Med), PhDc, Mark N. Lurie, PhDe, William MacLeod, PhDc,f, Given Maletec, Sergio 
Carmona, MBBCh, FCPath (Haem)g, Gayle Sherman, MBBCh, MMed (Haem), DCH, DTM&H, 
PhDh,i, and Matthew P. Fox, DSc, MPHc,f,j
aVanderbilt Institute for Global Health, Vanderbilt University, Nashville, TN, USA
bVanderbilt University Department of Medicine, Division of Infectious Diseases, Nashville, TN, 
USA
cHealth Economics and Epidemiology Research Office (HE2RO), Department of Internal 
Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa
dVanderbilt University Department of Pediatrics, Nashville, TN, USA
eDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA
fDepartment of Global Health, Boston University, Boston, MA, USA
gSouth Africa National Laboratory Health Service, Johannesburg, South Africa
hDepartment of Paediatrics & Child Health, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa
iCentre for HIV and STI, National Institute for Communicable Diseases, Johannesburg, South 
Africa
jDepartment of Epidemiology, Boston University School of Public Health, Boston University, 
Boston, MA, USA
Abstract
Objective—Retention in HIV care, particularly among postpartum women, is a challenge to 
national antiretroviral therapy (ART) programs. Retention estimates may be underestimated due to 
unreported transfers. We explored mobility and clinic switching among patients considered lost to 
follow-up (LTFU).
Design—Observational cohort study.
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Methods—Of 788 women initiating ART during pregnancy at six public clinics in Johannesburg, 
South Africa, 300 (38.1%) were LTFU (no visit ≥3 months). We manually searched for these 
women in the South African National Health Laboratory Services database to assess continuity of 
HIV care. We used geographic information systems tools to map mobility to new facilities.
Results—Over one–third (37.6%) of women showed evidence of continued HIV care after 
LTFU. Of these, 67.0% continued care in the same province as the origin clinic. Compared to 
those who traveled outside of the province for care, these same-province “clinic shoppers” stayed 
out-of-care longer [median 373 days (IQR: 175–790) vs. 175.5 days (IQR: 74–371)] and had a 
lower CD4+ cell count upon re-entry [median 327 cells/µL (IQR: 196–576) vs. 493 cells/µL (IQR: 
213–557). When considering all women with additional evidence of care as engaged in care, 
cohort LTFU dropped from 38.1% to 25.0%.
Conclusions—We found evidence of continued care after LTFU and identified local and 
national clinic mobility among postpartum women. Laboratory records do not show all clinic visits 
and manual matching may have been under- or overestimated. A national health database linked to 
a unique identifier is necessary to improve reporting and patient care among highly mobile 
populations.
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Introduction
South Africa’s government launched a universal test-and-treat policy to provide 
antiretroviral therapy (ART) to all HIV-positive people – regardless of CD4+ cell count – in 
September 2016.1 With more people living with HIV than any other country in the world, 
South Africa already had the largest ART program before this ambitious development.2 
Expanded ART availability has altered dramatically the health and quality of life of people 
living with HIV/AIDS, with an estimated life expectancy gain of 11.3 years between 2003 
and 2011 due to ART3 and a 77% decrease in HIV transmission among serodiscordant 
couples.4 However, the rapid scale-up of the national ART program has put tremendous 
pressure on the limited resources of a public health sector that is hurrying to meet immense 
need. The positive impact of life expectancy gains and improved health through expanded 
ART availability will only be realized if eligible individuals access care, remain in care and 
adhere to treatment.
Despite widespread availability of ART, approximately 162,445 people died of AIDS in 
South Africa in 2015, representing nearly one–third of the country’s total deaths.5 Many of 
these deaths could have been avoided through earlier engagement and improved retention in 
HIV care. The problem of patient drop-out, or loss to follow-up (LTFU), within the public-
sector in South Africa has been well documented.6,7 A large collaborative analysis of eight 
cohorts initiating ART across South Africa found that patient drop-out increased with 
duration on treatment, and by 36 months, 29% were LTFU.6 However, misclassification of 
retention outcomes likely clouds our understanding of the true magnitude of LTFU. As with 
much of sub-Saharan Africa, HIV care in most of South Africa is provided in decentralized 
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clinics; patient data typically are captured first on paper files then later entered electronically 
into database programs. No unique patient identifier is used. As a result, when patients move 
between facilities, due to the highly mobile nature of the population or local “clinic 
shopping,” patient data typically are not transferred to the new facility. Clinics are not yet 
fully equipped to track patient movement from one facility to another, so a LTFU patient 
may actually be engaged in care elsewhere. Therefore, estimates of LTFU typically represent 
patient drop-out only from the perspective of a single clinic rather than system-wide 
retention, a serious limitation. Work in Uganda tracking a sample of patients considered lost 
has shown that retention estimates were underestimated by “silent transfers” (transfers not 
reported to the sending facility) between clinics and by unreported mortality.8–12 However, 
manually tracing patients is resource intensive, difficult to bring to scale, and usually relies 
upon self-reported retention.
Access to ART for all HIV-positive pregnant women through Option B+, introduced in 
South Africa in 2015,13 has helped to reduce mother-to-child transmission of HIV to the 
point where near-elimination is now thought possible.14 Despite this astounding 
achievement, there is mounting evidence that women who initiate ART during pregnancy 
may be at very high risk of LTFU,15–18 with re-engagement in routine HIV care after 
delivery a particular concern.19,20 Suggested reasons for this high LTFU include a lack of 
perception of need for treatment,16,21 increased financial burden,16,22 and stigma.23–26 In 
our recent work, we have observed that HIV-positive women reported difficulty in providing 
a “valid reason” to be seen at a clinic after giving birth; while pregnant, clinic attendance is 
accepted, but after delivery, clinic attendance and medication adherence are viewed with 
societal and familial suspicion.27 Additionally, postpartum women in South Africa may be a 
particularly mobile group, due in part to a tradition of returning to one’s rural home after 
delivery to receive care from family members.16,24,28 We wished to explore how women 
travel and access care during the peripartum period, which is characterized by frequent 
mobility.
While frequent population mobility in South Africa is known to contribute to the spread of 
HIV29,30 and is theorized to minimize the gains of ART as prevention,31 its impact on both 
patient care and programmatic estimates of retention in care is poorly understood. Better 
estimates of retention in HIV care would allow for resources to be targeted where they are 
most needed. Because South Africa does not have a national HIV database that allows 
tracking patients across treatment sites, but does have a national provider of laboratory 
services, we developed a novel method for tracking movement between HIV clinics and 
used an existing laboratory database to determine the continuity of HIV care and the 
frequency of clinic switching among postpartum women considered LTFU in South Africa. 
We then used geographic information system (GIS) mapping techniques to describe mobility 
among women seeking continued care.
Methods
Study population
To determine the proportion of women who continued HIV care after being considered 
LTFU, we conducted a retrospective cohort study using data from the Right to Care (RTC) 
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Clinical HIV cohort stored in an electronic database called TherapyEdge-HIV™. The 
database contains information on all routine clinical care for HIV-positive patients at 
participating public health clinics in Johannesburg, South Africa. Data are maintained and 
provided by the Health Economics and Epidemiology Research Office (HE2RO) in 
Johannesburg. At six Johannesburg public health clinics supported by Right to Care, 788 
HIV-positive women initiated ART during pregnancy from January 1, 2012 – July 31, 2013. 
At this time, national guidelines called for initiation of lifelong ART for pregnant women 
with CD4+ cell counts ≤350 cells/µl. Of these 788 women, 300 (38.1%) were considered 
lost to follow-up by August 2015, defined as no clinic visit ≥3 months after the last 
scheduled visit; these 300 comprised our study population.
Patient tracing
The South African National Health Laboratory Service (NHLS) conducts nearly all 
laboratory testing within the public sector HIV treatment program throughout the country 
and keeps a database of all lab results within a central data warehouse. While not a formal 
research database, patient results can be queried. To determine whether women initiating 
ART at a RTC-supported clinic received care after being lost to follow up, we manually 
traced these 300 women in the NHLS database using two methods. First, in September 2015, 
we searched using the query tool of the NHLS TrakCare Lab online website, which is 
available to clinicians and researchers via secure log-in. Each woman was queried a 
minimum of five times using combinations of full and/or partial name(s), surname and date 
of birth (DOB). Second, we searched for all 300 women again in the complete NHLS 
National HIV Cohort, using a probabilistic Jaro-Winkler matching algorithm for name and 
surname set to a minimum match probability of 91%, using SAS 9.4 (SAS Institute, Cary, 
NC), followed by manually matching on exact DOB.
Outcome definitions
When NHLS records were found, we categorized the facility where a given lab record was 
ordered as being either the origin clinic – where ART was initiated – or a new destination 
facility. Starting with the date last seen at the origin clinic, we defined continued HIV care as 
accessing care at a new facility at any time during the follow-up period, as demonstrated by: 
a) at least one CD4 or viral load test on record, or b) any record from a new ART clinic, as 
shown by the facility name on the lab report.
Analysis
Patient characteristics were summarized using counts and proportions for categorical 
variables; medians and interquartile ranges (IQR) for continuous data. To assess patterns of 
movement between clinics, decimal degree coordinates were obtained for each facility 
where a woman received care by NHLS records or by query on Google Maps. Using 
ArcMap® 10.3.1 (Esri, Inc., Redlands, CA), the coordinates were imported to shapefiles 
with a WGS 1984 coordinate system. We connected origin and destination facilities using 
ArcMap’s XY-to-line tool, and distance between the origin and destination facilities was 
calculated by using an online tool (The Great Circle Calculator by Ed Williams, 
Williams.best.vwh.net/gccalc.htm) to compare the X/Y coordinates.
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This study was approved by the Institutional Review Board of Vanderbilt University and the 
Human Research Ethics Committee of the University of the Witwatersrand.
Results
Patient characteristics of the 300 women who were considered LTFU after initiating 
antiretroviral therapy during pregnancy at six HIV clinics in Johannesburg are shown in 
Table 1. Median age and CD4+ cell count at ART initiation was 28.6 years (IQR: 24.8 – 
32.7) and 267 cells/µL (IQR: 197 – 334), respectively. Nearly one–third were not self-
identified South African nationals. The median time between ART initiation and the last 
clinic visit at the initiation site was about 3 months (104 days, IQR: 28 – 251).
Figure 1 shows the results of tracing women in the NHLS database. We found at least one 
record – including from the origin clinic – for nearly all women (93.7%). Of these, over 
one–third (37.6%) showed evidence of continued HIV care. If we consider all 103 women 
with a subsequent lab record as engaged in care, LTFU in the original cohort of 788 pregnant 
women initiating ART drops from 38.1% (95%CI: 34.7 – 41.5%) to 25.0% (95%CI: 22.1% 
– 28.1%).
Among the 103 who continued HIV care, the median time out of care was 304.5 days (IQR: 
100 – 582) and median CD4 upon reentry to care was 355.5 cells/µL (IQR: 204.5 – 564) 
(Figure 1). Overall, CD4 values from the last origin clinic visit and the first visit at the new 
facility were nearly unchanged, with a median increase of 50 cells/µL (IQR: −85 – 126). 
Viral load results from the new facility were available for 42/103 women (40.8%); of these, 
24 (57.1%) were virally suppressed per South African treatment guidelines (<50 copies/
mL),13 11 (26.2%) had viral loads 50–1000 copies/mL and 7 (16.7%) had >1000 copies/mL.
Figures 2a and 2b illustrate the movement between the origin and new facilities. Median 
distance between the origin and new facility was 21.8 km (IQR: 8.9 – 276.4). Two–thirds 
(67.0%) of the 103 women who continued HIV care did so in Gauteng Province – the same 
province as the origin clinic – with a median distance of 9.9 km (range: 0.6 – 81.6) between 
facilities (Figure 2a). For the remaining 33% who continued care elsewhere in South Africa, 
the median distance between facilities was 376 km (276 – 527) (Figure 2b). Women who 
visited a new facility within Gauteng Province stayed out of care longer (median 373.0 days 
vs. 175.5 days) and their median CD4 values upon return were lower (327 vs. 493 cells/µL) 
than those who sought care elsewhere in South Africa (Figure 1). Those who continued care 
outside of Gauteng Province had a greater CD4 increase (median 79 cells/µL; IQR: −55 – 
170) upon re-entering care than those who sought care within Gauteng (median: 25 cells/µL; 
IQR: −94.5 – 115.5).
Our analysis also found further movement beyond just the first new facility. Overall, 103 
(37.6%) women accessed at least one new facility, 18 (6.4%) accessed two or more, 6 
(2.1%) accessed three or more, and 2 (0.7%) accessed four distinct facilities after dropping 
out of care from the origin site. Figures 3a and 3b display the movement of the 18 women 
who accessed at least two new clinics, showing that movement occurred both within 
Gauteng Province and to outside provinces.
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Discussion
We found substantial evidence of continued HIV care among women considered LTFU after 
initiating ART during pregnancy, both within the same city and in other provinces within 
South Africa. If we consider all of the 103 women who had records at a new clinic as 
engaged in care, LTFU in the original cohort drops substantially, from 38.1% to 25.0%, a 
13% underestimation of retention in care. It is important to note that laboratory records are a 
limited proxy for retention, as they do not show the full picture of clinic visits, pharmacy 
pick-ups, or adherence, but we found evidence to suggest that current continuum of care 
estimates of retention may be overly pessimistic due to outcome misclassification. In our 
study, over one–third of women considered LTFU had accessed care at a new site, often 
referred to a “silent transfer”11 in retention research.
To our knowledge, this is the first study to spatially analyze movement between health care 
facilities. In doing so, we discovered that most women accessed care at a new facility close 
to where they initiated ART, while another one–third accessed care in a different province. 
We characterize those who accessed care close to their origin clinic as “clinic shoppers” and 
we were surprised to find that this group had poorer health outcomes upon returning to care 
than those who accessed care away from Johannesburg. This rather counterintuitive finding 
may be because women who traveled out of the province were more motivated to remain in 
care, or that those who returned to care in Gauteng Province had already traveled to a rural 
home after delivery and returned to care only upon resettling in Gauteng. It is also important 
to note that among a small sample, we found evidence of frequent clinic switching: two, 
three and four new facilities, both within Gauteng Province and outside, after seeming to 
drop out of the initiation site. Stigma, lack of purposeful disclosure, and fear of accidental 
disclosure have been identified as substantial barriers to retention in postpartum care,23,25–27 
and the desire to seek anonymity may influence the decision to “shop” around to local 
facilities. Therefore, women in the “clinic shopper” group may have dropped out of care and 
delayed returning until sickness, then chose to return to a different clinic. Follow-up 
qualitative research to explore women’s mobility around the time of delivery and how it 
impacts retention in care and choice of facility is needed to better understand these 
quantitative findings. Our study demonstrated mobility among those who accessed care, but 
the mobility of women who did not access care is not represented; thus, the mobility within 
our study population – whether local, national or international – likely is higher than we 
found through tracing national lab records.
While we found evidence of continued HIV care, the outlook is still suboptimal. Women 
dropped out of care quickly after initiating ART – the median time from initiation visit to 
last clinic visit was just 3 months (104 days, IQR: 28–251) – which highlights the need for 
enhanced retention counseling given the expansion of ART through the universal test-and-
treat policy. Even if we reclassify all 103 women with just one continued visit as engaged in 
care, 25% LTFU is still unacceptably high. All of the women in this cohort initiated ART 
during pregnancy; dropping out of care puts them at risk of immunosuppression and death, 
as well as transmission of the virus to the baby. Furthermore, we found that women are 
suspending care for extended periods of time before re-engaging, with CD4 counts 
remaining relatively low and viral loads increasing during the time out of care. This was 
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most apparent in the group of “clinic shoppers” seeking alternative clinics in Gauteng 
Province, whose median time between lab tests was over a year (373 days, IQR: 175–790) 
despite eventually going to a new facility very close (median <10km) to where they started. 
Overall, fewer than half (40.3%) of those who accessed a new facility received a viral load 
test. Consistent retention in postpartum HIV care remains a substantial challenge in South 
Africa, both from an individual and a health systems perspective, and one that may be 
exacerbated by expansion of ART availability through Option B+ and test-and-treat policies.
This study adds to the small body of work within the sub-Saharan African region examining 
continued care among individuals considered lost to follow-up after ART initiation.11,32–34 
Our study manually linked existing data sources to search for all lost patients, rather than 
physically tracing a sample of lost patients in the community. This method has advantages 
and disadvantages. One advantage is that we did not rely on patient-reported retention, 
which may be subject to bias, and when available, lab records contain extremely useful 
clinical data. Also, because clinicians in South Africa have access to NHLS’s web query 
tool, this method of patient tracing could be used to search national lab results in real-time 
during patient care. However, even if this were possible, given time and resource constraints, 
the manual searching of patients is cumbersome, requiring patience and diligence. For 
example, for a patient with the first name Beverly, we found matching records with five 
spellings: “Beverly,” “Beverley,” “Bereley,” “Bevelly” and “Bervely.” In addition to 
misspellings, we often encountered confusion between first and middle names, and date of 
birth transposing errors. Manually searching for lost patients took many hours and is more 
feasible as a research exercise than as a routine clinical follow-up. While we used two 
different techniques for matching records, it is possible that we still missed records or 
misclassified matches, resulting in either overmatching or undermatching. Also, due to 
differing periods of follow-up time, some participants had more time to meet the definition 
of continued in care than others.
An additional limitation is that lab records do not contain pregnancy information, so we do 
not know the timing of delivery and cannot determine the transition from antenatal to 
postpartum care. However, considering that the median time out care among women who 
continued care was over 300 days, we can assume that most were no longer pregnant with 
the index pregnancy. Death records also were unavailable, so ascertainment of death may be 
incomplete. Furthermore, lab records do not tell us why the patient accessed care – whether 
for a routine visit or otherwise – or the complete timeline of continued care, as a lab-based 
test may not have been completed at each visit. Additionally, almost 30% of our cohort self-
identified nationality other than South African, but the lab database only contained records 
from within South Africa; thus, we cannot comment on cross-border mobility. For these 
reasons, we consider this work to be a proof-of-concept to demonstrate that women are 
continuing care after LTFU in the absence of a national, linked clinical database.
Our findings highlight the difficulty of producing accurate estimates of retention in care in 
the context of frequent mobility and clinic switching. This movement affects not only 
estimates of retention in care for epidemiologic research, but also real-world patient care 
since clinical data from other sites are unavailable in real time. We have demonstrated that 
patients are moving facilities, but unless a patient requests a formal transfer, their records do 
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not move. As countries like South Africa weigh their future health care reporting systems, 
results like these emphasize the urgent need for a national database with improved data 
quality management, linked by a unique identifier to improve health services for a highly 
mobile population.
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Figure 1. 
Results of tracing patients considered lost to follow-up (n=300)
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Figure 2. 
a. Movement to facilities within Gauteng Province (n=69)
b. Movement to facilities outside of Gauteng Province (n=34)
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Figure 3. 
a. Movement to facilities within Gauteng Province by those attending two new facilities 
(n=18)
b. Movement to facilities outside of Gauteng Province by those attending two new facilities 
(n=18)
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Table 1
Characteristics of the study participants (n=300)
Patient characteristic Total
Age at ART initiation, median (IQR) 28.6 (24.8–32.7)
Age at ART initiation, n (%)
  Younger than 25 years 82 (27.3)
  25–32 years 149(49.7)
  33 years and older 69 (23.0)
CD4+ cell count at ART initiation (cells/µL), median (IQR) 267 (197–334)
CD4+ cell count at ART initiation, n (%)
  Less than 200 cells/µL 65 (21.7)
  200–350 cells/µL 137 (45.7)
  Over 350 cells/µL 57 (19.0)
  Missing 41 (13.7)
Nationality, n (%)
  South Africa 207 (69.0)
  Outside of South Africa 89 (29.7)
  Missing 4 (1.33)
Employment status, n (%)
  Employed 103 (34.3)
  Not employed 161 (53.7)
  Missing 36 (12.0)
Highest level of education attained
  Primary school or less 20 (6.7)
  Some secondary school 140 (46.7)
  Completed secondary school 101 (33.7)
  Missing 39 (13.0)
IQR, interquartile range
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